F M Investments LLC Invests $574,000 in GeneDx Holdings Corp. (NASDAQ:WGS)

F M Investments LLC purchased a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 7,469 shares of the company's stock, valued at approximately $574,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MCF Advisors LLC grew its position in GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after buying an additional 182 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of GeneDx in the fourth quarter valued at about $28,000. KLP Kapitalforvaltning AS purchased a new stake in shares of GeneDx in the fourth quarter valued at about $200,000. Evolution Wealth Advisors LLC acquired a new position in shares of GeneDx during the fourth quarter worth about $202,000. Finally, Victory Capital Management Inc. acquired a new stake in GeneDx in the fourth quarter valued at about $209,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Kevin Feeley sold 922 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84. Following the sale, the chief financial officer now owns 5,446 shares in the company, valued at $515,845.12. This trade represents a 14.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Katherine Stueland sold 46,594 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $89.62, for a total value of $4,175,754.28. Following the transaction, the chief executive officer now owns 1,720 shares in the company, valued at $154,146.40. This trade represents a 96.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 138,780 shares of company stock valued at $12,907,437 over the last 90 days. Insiders own 27.30% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts have recently commented on WGS shares. The Goldman Sachs Group raised their price target on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. TD Cowen boosted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $72.33.

GeneDx Price Performance

Shares of WGS stock traded down $3.94 during trading hours on Wednesday, hitting $98.28. The company's stock had a trading volume of 760,656 shares, compared to its average volume of 676,525. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $8.63 and a twelve month high of $115.60. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -50.14 and a beta of 1.93. The business has a fifty day moving average of $91.91 and a 200-day moving average of $78.94.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. As a group, equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.